• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

“细胞因子风暴”,不仅在 COVID-19 患者中。小型综述。

"Cytokine storm", not only in COVID-19 patients. Mini-review.

机构信息

IV-th Department of Medicine, Safarik University, Kosice, Slovakia.

出版信息

Immunol Lett. 2020 Dec;228:38-44. doi: 10.1016/j.imlet.2020.09.007. Epub 2020 Sep 29.

DOI:10.1016/j.imlet.2020.09.007
PMID:33007369
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7524442/
Abstract

Cytokine storm is a form of uncontrolled systemic inflammatory reaction activated by a variety of factors and leading to a harmful homeostatic process, even to patient's death. Triggers that start the reaction are infection, systemic diseases and rarely anaphylaxis. Cytokine storm is frequently mentioned in connection to medical interventions such as transplantation or administration of drugs. Presented mini-review would like to show current possibilities how to fight or even stop such a life-threatening, immune-mediated process in order to save lives, not only in COVID-19 patients. Early identification of rising state and multilevel course of treatment is imperative. The most widely used molecule for systemic treatment remains tocilizumab. Except for anti IL-6 treatment, contemporary research opens the possibilities for combination of pharmaceutical, non-pharmaceutical and adjunctive treatment in a successful fight with consequences of cytokine storm. Further work is needed to discover the exact signaling pathways that lead to cytokine storm and to determine how these effector molecules and/or combination of processes can help to resolve this frequently fatal episode of inflammation. It is a huge need for all scientists and clinicians to establish a physiological rational for new therapeutic targets that might lead to more personalized medicine approaches.

摘要

细胞因子风暴是一种由多种因素激活的失控性全身炎症反应,导致有害的体内平衡过程,甚至导致患者死亡。引发反应的触发因素有感染、系统性疾病,极少数情况下还有过敏反应。细胞因子风暴经常与移植或药物治疗等医学干预措施相关联。本文综述旨在展示目前有哪些可能的方法可以对抗甚至阻止这种危及生命的免疫介导过程,以拯救生命,而不仅仅是在 COVID-19 患者中。早期识别上升状态和多水平治疗过程至关重要。目前最广泛用于全身治疗的分子仍然是托珠单抗。除了抗 IL-6 治疗外,当代研究还为药物、非药物和辅助治疗的联合治疗开辟了可能性,以成功应对细胞因子风暴的后果。还需要进一步的研究来发现导致细胞因子风暴的确切信号通路,并确定这些效应分子和/或过程的组合如何有助于解决这种经常致命的炎症发作。所有科学家和临床医生都需要建立新的治疗靶点的生理合理性,这可能会导致更个性化的医疗方法。

相似文献

1
"Cytokine storm", not only in COVID-19 patients. Mini-review.“细胞因子风暴”,不仅在 COVID-19 患者中。小型综述。
Immunol Lett. 2020 Dec;228:38-44. doi: 10.1016/j.imlet.2020.09.007. Epub 2020 Sep 29.
2
Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review.托珠单抗治疗细胞因子风暴综合征的 SARS-CoV-2 患者:一项叙述性综述。
Rev Recent Clin Trials. 2021;16(2):138-145. doi: 10.2174/1574887115666200917110954.
3
Targeting Cytokine Storm to Manage Patients with COVID-19: A Mini-Review.靶向细胞因子风暴以管理 COVID-19 患者:小型综述。
Arch Med Res. 2020 Oct;51(7):608-612. doi: 10.1016/j.arcmed.2020.06.012. Epub 2020 Jun 19.
4
Cytokine storm in COVID-19: from viral infection to immune responses, diagnosis and therapy.COVID-19 中的细胞因子风暴:从病毒感染到免疫反应、诊断和治疗。
Int J Biol Sci. 2022 Jan 1;18(2):459-472. doi: 10.7150/ijbs.59272. eCollection 2022.
5
Clinical outcomes in COVID-19 patients treated with tocilizumab: An individual patient data systematic review.托珠单抗治疗 COVID-19 患者的临床结局:一项个体患者数据系统评价。
J Med Virol. 2020 Nov;92(11):2516-2522. doi: 10.1002/jmv.26038. Epub 2020 Jun 9.
6
Cytokines and COVID-19: friends or foes?细胞因子与 COVID-19:是敌是友?
Hum Vaccin Immunother. 2020 Oct 2;16(10):2363-2365. doi: 10.1080/21645515.2020.1799669. Epub 2020 Aug 25.
7
Comparative Survival Analysis of Immunomodulatory Therapy for Coronavirus Disease 2019 Cytokine Storm.比较免疫调节疗法治疗 2019 年冠状病毒病细胞因子风暴的生存分析。
Chest. 2021 Mar;159(3):933-948. doi: 10.1016/j.chest.2020.09.275. Epub 2020 Oct 17.
8
Immunomodulation using CONVEHY® for COVID-19: from the storm to the cytokine anticyclone.使用CONVEHY®对新型冠状病毒肺炎进行免疫调节:从风暴到细胞因子反气旋
Rev Esp Anestesiol Reanim (Engl Ed). 2021 Feb;68(2):107-112. doi: 10.1016/j.redar.2020.08.001. Epub 2020 Aug 29.
9
Tocilizumab as a Treatment for 'Cytokine Storm Syndrome' in COVID-19: A Case Report.托珠单抗治疗 COVID-19 中的“细胞因子风暴综合征”:一例报告。
Acta Med Indones. 2021 Apr;53(2):194-201.
10
Review on therapeutic targets for COVID-19: insights from cytokine storm.关于 COVID-19 的治疗靶点综述:细胞因子风暴的启示。
Postgrad Med J. 2021 Jun;97(1148):391-398. doi: 10.1136/postgradmedj-2020-138791. Epub 2020 Oct 2.

引用本文的文献

1
Cytokine Storm in COVID-19: Exploring IL-6 Signaling and Cytokine-Microbiome Interactions as Emerging Therapeutic Approaches.COVID-19 中的细胞因子风暴:探索 IL-6 信号和细胞因子-微生物组相互作用作为新兴治疗方法。
Int J Mol Sci. 2024 Oct 24;25(21):11411. doi: 10.3390/ijms252111411.
2
Vaping-associated illness: a reassessment.电子烟相关疾病:重新评估
Int J Emerg Med. 2024 Sep 2;17(1):107. doi: 10.1186/s12245-024-00692-4.
3
The critical impacts of cytokine storms in respiratory disorders.细胞因子风暴在呼吸系统疾病中的关键影响。

本文引用的文献

1
Amelioration of COVID-19-related cytokine storm syndrome: parallels to chimeric antigen receptor-T cell cytokine release syndrome.新型冠状病毒肺炎相关细胞因子风暴综合征的改善:与嵌合抗原受体T细胞细胞因子释放综合征的相似之处
Br J Haematol. 2020 Aug;190(3):e150-e154. doi: 10.1111/bjh.16961. Epub 2020 Jul 16.
2
Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19.羟氯喹治疗 COVID-19 住院患者的观察性研究。
N Engl J Med. 2020 Jun 18;382(25):2411-2418. doi: 10.1056/NEJMoa2012410. Epub 2020 May 7.
3
Pharmacological (or Synthetic) and Nutritional Agonists of PPAR-γ as Candidates for Cytokine Storm Modulation in COVID-19 Disease.
Heliyon. 2024 Apr 17;10(9):e29769. doi: 10.1016/j.heliyon.2024.e29769. eCollection 2024 May 15.
4
SNP (A > G - rs13057211) but not GT(n) polymorphism in HMOX-1 promotor gene is associated with COVID-19 mortality.SNP(A>G-rs13057211)但不是 HMOX-1 启动子基因中的 GT(n)多态性与 COVID-19 死亡率相关。
BMC Pulm Med. 2023 Dec 21;23(1):514. doi: 10.1186/s12890-023-02785-x.
5
IKK2/NFkB signaling controls lung resident CD8 T cell memory during influenza infection.IKK2/NFkB 信号通路在流感感染过程中控制肺驻留 CD8 T 细胞记忆。
Nat Commun. 2023 Jul 19;14(1):4331. doi: 10.1038/s41467-023-40107-1.
6
Influenza virus causes lung immunopathology through down-regulating PPARγ activity in macrophages.流感病毒通过下调巨噬细胞中 PPARγ 的活性引起肺部免疫病理学改变。
Front Immunol. 2022 Aug 25;13:958801. doi: 10.3389/fimmu.2022.958801. eCollection 2022.
7
Tobacco product use and the risks of SARS-CoV-2 infection and COVID-19: current understanding and recommendations for future research.烟草制品使用与 SARS-CoV-2 感染和 COVID-19 风险:当前的认识和对未来研究的建议。
Lancet Respir Med. 2022 Sep;10(9):900-915. doi: 10.1016/S2213-2600(22)00182-5. Epub 2022 Aug 16.
8
Comprehensive Cytokine Profiling of Patients with COVID-19 Receiving Tocilizumab Therapy.接受托珠单抗治疗的 COVID-19 患者的全面细胞因子分析。
Int J Mol Sci. 2022 Jul 19;23(14):7937. doi: 10.3390/ijms23147937.
9
Comparing the Cytokine Storms of COVID-19 and Pandemic Influenza.比较 COVID-19 和大流行性流感的细胞因子风暴。
J Interferon Cytokine Res. 2022 Aug;42(8):369-392. doi: 10.1089/jir.2022.0029. Epub 2022 Jun 7.
10
Fostering experimental and computational synergy to modulate hyperinflammation.促进实验与计算的协同作用来调节过度炎症。
Trends Immunol. 2022 Jan;43(1):4-7. doi: 10.1016/j.it.2021.11.004. Epub 2021 Nov 26.
PPAR-γ 药理学(或合成)激动剂和营养激动剂作为 COVID-19 疾病细胞因子风暴调节的候选物。
Molecules. 2020 Apr 29;25(9):2076. doi: 10.3390/molecules25092076.
4
A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease.一项伊曲替尼(一种选择性 JAK1 抑制剂)治疗急性移植物抗宿主病患者的 1 期临床试验。
Blood Adv. 2020 Apr 28;4(8):1656-1669. doi: 10.1182/bloodadvances.2019001043.
5
Associations between immune-suppressive and stimulating drugs and novel COVID-19-a systematic review of current evidence.免疫抑制与刺激药物和新型冠状病毒肺炎之间的关联——当前证据的系统评价
Ecancermedicalscience. 2020 Mar 27;14:1022. doi: 10.3332/ecancer.2020.1022. eCollection 2020.
6
The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease.细胞因子(包括白细胞介素 6)在 COVID-19 诱导性肺炎和巨噬细胞活化综合征样疾病中的作用。
Autoimmun Rev. 2020 Jun;19(6):102537. doi: 10.1016/j.autrev.2020.102537. Epub 2020 Apr 3.
7
TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib.COVID-19 细胞因子风暴中的 TH17 反应:JAK2 抑制剂 Fedratinib 的一个新靶点。
J Microbiol Immunol Infect. 2020 Jun;53(3):368-370. doi: 10.1016/j.jmii.2020.03.005. Epub 2020 Mar 11.
8
COVID-19: combining antiviral and anti-inflammatory treatments.2019冠状病毒病:联合抗病毒与抗炎治疗
Lancet Infect Dis. 2020 Apr;20(4):400-402. doi: 10.1016/S1473-3099(20)30132-8. Epub 2020 Feb 27.
9
Cytokine Release Syndrome: Current Perspectives.细胞因子释放综合征:当前观点
Immunotargets Ther. 2019 Oct 29;8:43-52. doi: 10.2147/ITT.S202015. eCollection 2019.
10
In the Eye of the Storm: Immune-mediated Toxicities Associated With CAR-T Cell Therapy.风暴之眼:与CAR-T细胞疗法相关的免疫介导毒性
Hemasphere. 2019 Mar 29;3(2):e191. doi: 10.1097/HS9.0000000000000191. eCollection 2019 Apr.